Fostamatinib Fails to Improve Outcomes in Hypoxemic COVID Patients

(MedPage Today) -- The spleen tyrosine kinase inhibitor fostamatinib (Tavalisse) did not improve outcomes in adults hospitalized with COVID-19 and hypoxemia, according to a phase III trial published in JAMA Network Open.
In this exclusive MedPage...